Oncology & Cancer

Studying resistance to therapy in BRAF-mutated brain tumors

Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country—including ...

Oncology & Cancer

A new approach to metastatic melanoma discovered

Combining chemotherapy and BRAF oncogene inhibitors is an effective strategy for fighting metastatic melanoma, the leading cause of death from skin cancer in the world. This has been demonstrated in a study by researchers ...

Oncology & Cancer

Benefit of adjuvant dabrafenib, trametinib persists in melanoma

(HealthDay)—For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according ...

Medications

Pembrolizumab use supported in advanced melanoma

(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, ...

page 1 from 11